Biophysical properties of human antibody variable domains - PubMed (original) (raw)
Biophysical properties of human antibody variable domains
Stefan Ewert et al. J Mol Biol. 2003.
Abstract
There are great demands on the stability, expression yield and resistance to aggregation of antibody fragments. To untangle intrinsic domain effects from domain interactions, we present first a systematic evaluation of the isolated human immunoglobulin variable heavy (V(H)) and light (V(L)) germline family consensus domains and then a systematic series of V(H)-V(L) combinations in the scFv format. The constructs were evaluated in terms of their expression behavior, oligomeric state in solution and denaturant-induced unfolding equilibria under non-reducing conditions. The seven V(H) and seven V(L) domains represent the consensus sequences of the major human germline subclasses, derived from the Human Combinatorial Antibody Library (HuCAL). The isolated V(H) and V(L) domains with the highest thermodynamic stability and yield of soluble protein were V(H)3 and V(kappa)3, respectively. Similar measurements on all domain combinations in scFv fragments allowed the scFv fragments to be classified according to thermodynamic stability and in vivo folding yield. The scFv fragments containing the variable domain combinations H3kappa3, H1bkappa3, H5kappa3 and H3kappa1 show superior properties concerning yield and stability. Domain interactions diminish the intrinsic differences of the domains. ScFv fragments containing V(lambda) domains show high levels of stability, even though V(lambda) domains are surprisingly unstable by themselves. This is due to a strong interaction with the V(H) domain and depends on the amino acid sequence of the CDR-L3. On the basis of these analyses and model structures, we suggest possibilities for further improvement of the biophysical properties of individual frameworks and give recommendations for library design.
Copyright 2003 Elsevier Science Ltd.
Similar articles
- The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains.
Honegger A, Malebranche AD, Röthlisberger D, Plückthun A. Honegger A, et al. Protein Eng Des Sel. 2009 Mar;22(3):121-34. doi: 10.1093/protein/gzn077. Epub 2009 Jan 10. Protein Eng Des Sel. 2009. PMID: 19136675 - Domain interactions in antibody Fv and scFv fragments: effects on unfolding kinetics and equilibria.
Jäger M, Plückthun A. Jäger M, et al. FEBS Lett. 1999 Dec 3;462(3):307-12. doi: 10.1016/s0014-5793(99)01532-x. FEBS Lett. 1999. PMID: 10622716 - Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach.
Ewert S, Honegger A, Plückthun A. Ewert S, et al. Biochemistry. 2003 Feb 18;42(6):1517-28. doi: 10.1021/bi026448p. Biochemistry. 2003. PMID: 12578364 - Single chain antibody variable regions.
Bird RE, Walker BW. Bird RE, et al. Trends Biotechnol. 1991 Apr;9(4):132-7. doi: 10.1016/0167-7799(91)90044-i. Trends Biotechnol. 1991. PMID: 1367550 Review. - Structural significance of sequence variability in antibody complementarity-determining regions.
Abergel C, Tipper JP, Padlan EA. Abergel C, et al. Res Immunol. 1994 Jan;145(1):49-53. doi: 10.1016/s0923-2494(94)80043-x. Res Immunol. 1994. PMID: 8008969 Review. No abstract available.
Cited by
- Developability considerations for bispecific and multispecific antibodies.
Amash A, Volkers G, Farber P, Griffin D, Davison KS, Goodman A, Tonikian R, Yamniuk A, Barnhart B, Jacobs T. Amash A, et al. MAbs. 2024 Jan-Dec;16(1):2394229. doi: 10.1080/19420862.2024.2394229. Epub 2024 Aug 27. MAbs. 2024. PMID: 39189686 Free PMC article. Review. - A single-domain antibody library based on a stability-engineered human VH3 scaffold.
Lee NJ, Jung M, Yang HY, Shim H. Lee NJ, et al. Sci Rep. 2024 Jul 31;14(1):17747. doi: 10.1038/s41598-024-68680-5. Sci Rep. 2024. PMID: 39085444 Free PMC article. - Potent human neutralizing antibodies against Nipah virus derived from two ancestral antibody heavy chains.
Chen L, Sun M, Zhang H, Zhang X, Yao Y, Li M, Li K, Fan P, Zhang H, Qin Y, Zhang Z, Li E, Chen Z, Guan W, Li S, Yu C, Zhang K, Gong R, Chiu S. Chen L, et al. Nat Commun. 2024 Apr 6;15(1):2987. doi: 10.1038/s41467-024-47213-8. Nat Commun. 2024. PMID: 38582870 Free PMC article. - Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate.
Ma X, Wang M, Ying T, Wu Y. Ma X, et al. Antib Ther. 2024 Feb 16;7(2):114-122. doi: 10.1093/abt/tbae005. eCollection 2024 Apr. Antib Ther. 2024. PMID: 38566971 Free PMC article. Review. - Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies.
Aertker KMJ, Pilvankar MR, Prass TM, Blech M, Higel F, Kasturirangan S. Aertker KMJ, et al. MAbs. 2024 Jan-Dec;16(1):2318817. doi: 10.1080/19420862.2024.2318817. Epub 2024 Mar 6. MAbs. 2024. PMID: 38444390 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources